Final results of atrasentan + chemotherapy in men with mCRPC

Two years after the trial was stopped early (in April 2011), Quinn et al. have published the final results of the randomized, double-blind, placebo-controlled, Phase III trial of atrasentan + docetaxel + prednisone in men with metastatic castration-resistant prostate cancer (mCRPC). … READ MORE …

New data sound death knell for atrasentan in prostate cancer

About a decade ago, Abbott Laboratories started to investigate the potential of a selective endothelin receptor antagonist called atrasentan or Xinlay™ for the treatment of advanced forms of prostate cancer. … READ MORE …

Zibotentan not effective when used alone in treatment of mCRPC

According to a media release this morning from AstraZeneca, the company’s investigational drug zibotentan (also known as ZD4054) was not effective in extending the overall survival of patients with metastatic castration-resistant prostate cancer (mCRPC) in a randomized, double-blind, placebo-controlled Phase III trial. … READ MORE …

Your Wednesday news summary: November 19, 2008

Today’s reports cover such items as:

  • Disparities in cancer mortality between blacks and whites in the USA
  • Body mass, body fat distribution, and risk for prostate cancer
  • Risk for cancer in male carriers of BRCA mutations
  • A five-SNP genetic marker set and prostate cancer risk
  • Final results of the atrasentan trial in non-metastatic, HRPC patients
  • Is a rising plasma PDGF level an indicator for docetaxel failure? … READ MORE …